Diabetes Mellitus Clinical Trial
The aims of the present study were to investigate the association between adiponectin gene
polymorphisms and the response to rosiglitazone monotherapy in T2D patients.
A total of 255 T2D patients and 120 health volunteers were enrolled in this study. 42 T2D
patients with -11377(C/G) or +45(T/G) genotypes were selected to administrate orally 4mg
rosiglitazone daily for 12 consecutive weeks.
The aims of the present study were to investigate the association between adiponectin allele
+45(T/G) and -11377(C/G) polymorphisms and the response to rosiglitazone monotherapy in T2D
patients.
A total of 255 T2D patients (138 males, 117 females) aged from 25 to 70 years (mean 48.6 ±
10.7 years) and 120 healthy controls (53 females, 67 males) aged from 25 to 70 years(mean
47.1 ± 11.0 years) were enrolled to participate in this study. Physical examination, medical
history and serum biochemical tests were performed to identify healthy or T2D subjects. The
diagnosis criteria of T2D patients were made according to the World Health Organization in
1997 by fasting plasma glucose (FPG 7.0 mmol/L) and/or postprandial plasma glucose test
(PPG 11.1 mmol/L). The inclusion criteria of all subjects were that subjects had the range
of body mass index (BMI) from 18.5 to 30 kg/m2 and did not administrate any PPAR agonists in
the last 3 months. Patients who were receiving insulin treatment, pregnant or lactating
women, or with serious diseases such as acute myocardial infarction, cerebral vascular
accident, trauma, and kidney disease or liver disease were excluded from this study. Table 1
showed the characteristic profiles of T2D patients and healthy controls. There were no
statistical differences in the age, height, weight, and BMI value between T2D patients and
healthy controls. All subjects were recruited from local residents in Changsha city, Hunan
Province, P. R. China. The study protocol was approved by the Ethics Committee of Xiangya
School of Medicine, Central South University and written informed consents were obtained
before the start of this study. A total of 42 T2D patients (23 male, 19 female) were
randomly selected to be only treated with 4mg rosiglitazone daily for 12 consecutive weeks
without change in previous medications.
;
Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |